AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis - LARVOL DELTA

A Clinical Study on the Efficacy and Safety of Ivarmacitinib in Preventing aGVHD After HLA-matched Transplantation (clinicaltrials.gov) - P1/2 | N=32 | Not yet recruiting | Sponsor: Institute of Hematology & Blood Diseases Hospital, China

New P1/2 trial • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Graft versus Host Disease • Immunology • Myelodysplastic Syndrome • Transplantation

A prospective clinical study on advanced or metastatic non-small cell lung cancer in the first-line treatment of adebelimab combined with emacetinib +/- chemotherapy (ChiCTR) - P4 | N=68 | Recruiting | Sponsor: Henan Cancer Hospital; Henan Cancer Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

A randomized, double-blinded, placebo-controlled clinical trial of the efficacy and safety of SHR-0302 combine with Prednisone Acetate in the treatment of active arteritis (ChiCTR) - P4 | N=58 | Not yet recruiting | Sponsor: Zhongshan hospital, Fudan University; Zhongshan hospital, Fudan University

New P4 trial • Vasculitis

Ivarmacitinib in patients with moderate to severe atopic dermatitis stratified by baseline characteristics: a post-hoc analysis of a phase 3 clinical trial. (PubMed, J Dermatolog Treat) - "The overall incidence of adverse events and most of the adverse events of special interest were similar between Ivarmacitinib and placebo across all subgroups. Ivarmacitinib demonstrated efficacy and good tolerability in treating moderate to severe AD with diverse patient characteristics."

Clinical • Journal • P3 data • Retrospective data • Allergy • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A Trial of SHR0302 Tablets and SHR0302 Base Gel in Patients With Non-segmental Vitiligo (clinicaltrials.gov) - P2 | N=176 | Recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Dermatology • Immunology • Vitiligo

Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study (clinicaltrials.gov) - P2 | N=65 | Not yet recruiting | Sponsor: First Affiliated Hospital of Chongqing Medical University

New P2 trial • Hepatocellular Cancer • Immunology • Oncology • Solid Tumor

Upadacitinib Leads in Efficacy: A Bayesian Network Meta-Analysis of Four JAK Inhibitors in Moderate-To-Severe Atopic Dermatitis. (PubMed, Int J Dermatol) - "Among oral JAKis, upadacitinib 30 mg, followed by upadacitinib 15 mg, achieved the most consistent short-term efficacy, providing superior skin clearance and itch relief. Abrocitinib 200 mg and ivarmacitinib 8 mg showed intermediate benefits, whereas baricitinib displayed modest effects. These findings support a provisional efficacy preference for upadacitinib in managing moderate-to-severe AD unresponsive to biologic or topical therapies."

Clinical • Journal • Retrospective data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Ivarmacitinib in Advanced Solid Tumors: A Prospective, Two-Cohort, Two-Phase Exploratory Study in Patients Discontinued Due to Immune Intolerance (clinicaltrials.gov) - P2 | N=72 | Not yet recruiting | Sponsor: Fujian Cancer Hospital

New P2 trial • Solid Tumor

Ivarmacitinib provides rapid and continuous improvement in patients with moderate-to-severe atopic dermatitis: a focus on different anatomical regions. (PubMed, Inflammopharmacology) - P3 | "Ivarmacitinib provides rapid and continuous improvement across all anatomical regions in patients with moderate-to-severe AD."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

BH19 'JAK in the box?' Long-term safety concerns with oral Janus kinase inhibitors for alopecia areata. (PubMed, Br J Dermatol) - "The findings were synthesized to provide an overview of the safety profiles of baricitinib, ritlecitinib, deuruxolitinib, ivarmacitinib and other JAK inhibitors. Long-term safety data were scarce, with only one study (the phase IIb/III ALLEGRO trial on ritlecitinib) extending to 2 years, while others had follow-ups of 52 weeks or shorter...Given the chronic nature of AA and the potential for extended use of JAK inhibitors, further long-term studies are necessary to better assess the risks of malignancies, cardiovascular events and other rare but serious AEs associated with this drug class. Although short-term studies indicate efficacy and tolerability, the absence of longitudinal research underpins the need for cautious clinical use and informed patient decision making."

Journal • Review • Acne Vulgaris • Alopecia • Breast Cancer • Cardiovascular • Immunology • Infectious Disease • Melanoma • Myocardial Infarction • Oncology • Pain • Respiratory Diseases • Solid Tumor • Squamous Cell Carcinoma

Treatment of Moderate-to-Severe Atopic Dermatitis With Ivarmacitinib in Adolescents and Adults (clinicaltrials.gov) - P=N/A | N=1000 | Not yet recruiting | Sponsor: Xiangya Hospital of Central South University

New trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A Prospective, Single-arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Ivarmacitinib in the Treatment of Palmoplantar Pustulosis (clinicaltrials.gov) - P=N/A | N=60 | Recruiting | Sponsor: Xijing Hospital

New trial • Immunology • Psoriasis

Ivarmacitinib reduces the need for adding/escalating medications in moderate-to-severe rheumatoid arthritis patients: a post hoc analysis from a phase III trial. (PubMed, Front Pharmacol) - P3 | "Ivarmacitinib significantly reduces the need for adding/escalating medications compared to placebo, thereby potentially decreasing treatment burden. However, the post hoc, exploratory nature of this study requires further validation for the findings."

Journal • P3 data • Retrospective data • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Ivarmacitinib improves patient-reported outcomes across multiple domains in patients with active ankylosing spondylitis: a post hoc analysis of a phase II/III trial. (PubMed, Front Pharmacol) - P2/3 | "Ivarmacitinib significantly enhances multiple dimensions of PROs in active AS patients, supporting its utility in managing PROs in AS. Switching to ivarmacitinib also provides substantial benefits, this indicates that initiating ivarmacitinib treatment, even after an initial period of placebo leads to meaningful improvements in PROs."

Journal • P2/3 data • Retrospective data • Ankylosing Spondylitis • Back Pain • Immunology • Inflammatory Arthritis • Musculoskeletal Pain • Pain • Rheumatology • Seronegative Spondyloarthropathies

Re: "Ivarmacitinib for the Treatment of Adults with Severe Alopecia Areata: Results from a Phase 3 Trial.". (PubMed, J Am Acad Dermatol) - No abstract available

Journal • P3 data • Alopecia • Immunology

Ivarmacitinib: A Novel Selective JAK1 Inhibitor for the Treatment of Rheumatoid Arthritis-Letter to the Editor. (PubMed, Int J Rheum Dis) - No abstract available

Journal • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

A Trial of SHR0302 Tablets and SHR0302 Base Gel in Patients With Non-segmental Vitiligo (clinicaltrials.gov) - P2 | N=176 | Not yet recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd.

New P2 trial • Dermatology • Immunology • Vitiligo

Efficacy and safety of Ivarmacitinib in moderate-to-severe atopic dermatitis patients with or without previous systemic treatments: a post-hoc analysis of a phase III trial. (PubMed, J Dermatolog Treat) - P3 | "The adverse events were generally comparable between Ivarmacitinib and placebo groups, regardless of previous systemic treatments. Ivarmacitinib demonstrates good efficacy and a favorable safety profile in moderate-to-severe AD patients, irrespective of previous systemic treatments."

Clinical • Journal • P3 data • Retrospective data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Ivarmacitinib ointment for the treatment of adults with mild-to-moderate atopic dermatitis: phase 3 part of a randomized, double-blind, placebo-controlled, phase 2/3 clinical trial. (PubMed, Br J Dermatol) - "Twice-daily ivarmacitinib ointment (0.5% or 1%) produced rapid, durable, and well-tolerated improvement in signs, symptoms, and itch in adults with mild-to-moderate AD, supporting its potential as a safe, steroid-sparing topical therapy."

Clinical • Journal • P2/3 data • P3 data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Infectious Disease • Pruritus

A Novel JAK1 Inhibitor SHR0302 for Treatment of Chronic Graft-Verse-Host Disease: A Phase I Clinical Trial (ASH 2023) - "In summary, SHR0302 in combination with prednisone had a good safety and could achieve a high response for naïve-treatment cGVHD, which suggests that SHR0302 combination might become an optimal choice for naïve-treatment cGVHD."

Clinical • P1 data • Anemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Dyslipidemia • Graft versus Host Disease • Hypertriglyceridemia • Immunology • Metabolic Disorders • Transplantation

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study on the Efficacy and Safety of JAK1 Inhibitor Ivarmacitinib in Combination with Topical Corticosteroids in the Treatment of Moderate-to-Severe Chronic Hand Eczema (ChiCTR) - P4 | N=80 | Not yet recruiting | Sponsor: The First Hospital of Hebei Medical University; The First Hospital of Hebei Medical University

New P4 trial • Atopic Dermatitis • Contact Dermatitis • Dermatology • Immunology

Efficacy and Safety of Ivarmacitinib Sulfate Tablets in the Treatment of SAPHO Syndrome: A Single-Arm, Single-Center, Open-Label Clinical Trial (ChiCTR) - P4 | N=20 | Not yet recruiting | Sponsor: The First Affiliated Hospital of China Medical University; The First Affiliated Hospital of China Medical University

New P4 trial • Acne Vulgaris • Immunology

Ivarmacitinib for the Treatment of Sjögren’s Syndrome (ChiCTR) - P4 | N=30 | Not yet recruiting | Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University o

New P4 trial

Effect of Ivarmacitinib on Joint Swelling and Tenderness in Patients with Moderate-to-severe Rheumatoid Arthritis: A Post-hoc Study of a Phase III Clinical Trial (ACR Convergence 2025) - P3 | "Ivarmacitinib significantly improves joint swelling and tenderness in patients with moderate-to-severe RA. Moreover, ivarmacitinib 8 mg provides superior long-term benefits in improving tenderness of small joints than large joints."

Clinical • P3 data • Retrospective data • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Efficacy of Ivarmacitinib in Patients with Moderate-to-severe Rheumatoid Arthritis Stratified by Baseline Characteristics: A Post-hoc Study of a Phase III Clinical Trial (ACR Convergence 2025) - P3 | "Ivarmacitinib provides consistent efficacy across various subgroups in patient with moderate-to-severe RA."

Clinical • P3 data • Retrospective data • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • CRP